OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
+73.64%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$288M
AUM Growth
–
Cap. Flow
+$288M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
61.94%
Holding
31
New
31
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Apellis Pharmaceuticals
APLS
|
$31.4M |
| 2 |
IMAB
I-MAB
IMAB
|
$21.4M |
| 3 |
Celldex Therapeutics
CLDX
|
$18.2M |
| 4 |
Curis
CRIS
|
$18M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$15.7M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 94.1% |
| 2 | Financials | 1.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $31.4M | 10.87% | +548,374 | New | +$31.4M |
|
|
IMAB
2
I-MAB
IMAB
$340M
| $21.4M | 7.43% | +454,550 | New | +$21.4M |
|
|
3
Celldex Therapeutics
CLDX
$1.47B
| $18.2M | 6.32% | +1,041,398 | New | +$18.2M |
|
|
4
Curis
CRIS
$20.9M
| $18M | 6.25% | +2,200,000 | New | +$18M |
|
|
5
4D Molecular Therapeutics
FDMT
$288M
| $15.7M | 5.43% | +377,777 | New | +$15.7M |
|
6
PMV Pharmaceuticals
PMVP
$74.2M
| $15.4M | 5.33% | +250,000 | New | +$15.4M |
|
7
Arvinas
ARVN
$568M
| $15.2M | 5.26% | +178,500 | New | +$15.2M |
|
8
Gossamer Bio
GOSS
$562M
| $15.1M | 5.24% | +1,563,138 | New | +$15.1M |
|
|
XLRN
9
DELISTED
Acceleron Pharma Inc.
XLRN
| $14.4M | 4.98% | +112,363 | New | +$14.4M |
|
|
CCXI
10
DELISTED
ChemoCentryx, Inc.
CCXI
| $13.9M | 4.83% | +225,076 | New | +$13.9M |
|
11
Cardiff Oncology
CRDF
$140M
| $11.7M | 4.05% | +650,000 | New | +$11.7M |
|
12
Avidity Biosciences
RNA
$5.99B
| $11M | 3.8% | +430,041 | New | +$11M |
|
13
Dyne Therapeutics
DYN
$1.92B
| $10.1M | 3.51% | +481,538 | New | +$10.1M |
|
14
Taysha Gene Therapies
TSHA
$797M
| $8.5M | 2.95% | +320,440 | New | +$8.5M |
|
15
Arcus Biosciences
RCUS
$1.13B
| $7.79M | 2.7% | +300,000 | New | +$7.79M |
|
|
CALT
16
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
| $6.72M | 2.33% | +200,000 | New | +$6.72M |
|
17
FibroGen
FGEN
$47.8M
| $5.42M | 1.88% | +146,014 | New | +$5.42M |
|
18
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $5.22M | 1.81% | +295,238 | New | +$5.22M |
|
19
Revolution Medicines
RVMD
$7.1B
| $4.99M | 1.73% | +126,136 | New | +$4.99M |
|
20
Kura Oncology
KURA
$686M
| $4.9M | 1.7% | +150,000 | New | +$4.9M |
|
|
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.7M | 1.63% | +680,036 | New | +$4.7M |
|
22
MoonLake Immunotherapeutics
MLTX
$3.54B
| $4.55M | 1.58% | +400,000 | New | +$4.55M |
|
|
KRON
23
DELISTED
Kronos Bio
KRON
| $4.37M | 1.51% | +146,173 | New | +$4.37M |
|
|
JYAC
24
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $3.09M | 1.07% | +300,000 | New | +$3.09M |
|
|
VIE
25
DELISTED
Viela Bio, Inc. Common Stock
VIE
| $3.07M | 1.06% | +85,409 | New | +$3.07M |
|